


## WHAT IS CLAIMED IS:

1. A method for activating human antigen-presenting cells which comprises culturing human-derived antigen-presenting cells *in vitro* with at least one of the glycoside compounds represented by formula (A) or salts thereof:



wherein:

$R_1$  is H or OH;

$X$  is an integer of from 7 to 25;

$R_2$  is a substituent defined by any one of the following (a) to (e):

(a)  $-\text{CH}_2(\text{CH}_2)_Y\text{CH}_3$ ;

(b)  $-\text{CH}(\text{OH})(\text{CH}_2)_Y\text{CH}_3$ ;

(c)  $-\text{CH}(\text{OH})(\text{CH}_2)_Y\text{CH}(\text{CH}_3)_2$ ;


(d)  $-\text{CH}=\text{CH}(\text{CH}_2)_Y\text{CH}_3$ ; and

(e)  $-\text{CH}(\text{OH})(\text{CH}_2)_Y\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ;

wherein  $Y$  is an integer of from 5 to 17;


$R_3$  is H;

$R_4$  is OH,  $\text{NH}_2$ ,  $\text{NHCOCH}_3$  or




09721768.112700


one of  $R_5$  and  $R_6$  is H and the other is OH,




one of  $R_7$  and  $R_8$  is H and the other is OH.



$R_9$  is H,  $CH_3$ ,  $CH_2OH$ ,



2. The method of claim 1, wherein the glycoside compound is a compound represented by formula (B):



wherein:


$R_1$ ,  $X$  and  $R_2$  are as defined as in claim 1; and

$R_3$  to  $R_9$  are substituents defined by any one of the following (i) to (iii):



09721768.112700

(i) each of  $R_1$ ,  $R_6$  and  $R_8$  is H;



$R_4$  is OH or



$R_5$  is OH, or




$R_7$  is OH, or




and

$R_9$  is H, CH<sub>3</sub>, CH<sub>2</sub>OH,



or





(ii) each of  $R_1$ ,  $R_6$  and  $R_7$  is H;

$R_4$ ,  $R_5$  and  $R_9$  are as defined as in (i); and

$R_8$  is OH,

or

; or



(iii) each of  $R_1$ ,  $R_5$  and  $R_7$  is H;

each of  $R_4$ ,  $R_6$  and  $R_8$  is OH; and

09721768.112700

R<sub>9</sub> is H, CH<sub>3</sub>, or CH<sub>2</sub>OH.

3. The method of claim 2, wherein, in the glycoside compound, each of R<sub>3</sub>, R<sub>6</sub> and R<sub>8</sub> is H, each of R<sub>4</sub>, R<sub>5</sub> and R<sub>7</sub> is OH, and R<sub>9</sub> is CH<sub>2</sub>OH.

Q 4. The method of claim 2 or 3, wherein, in the glycoside compound, R<sub>2</sub> is any one of the substituents (b), (c) and (e).

5. The method of claim 4, wherein, in the glycoside compound, R<sub>1</sub> is H and R<sub>2</sub> is the substituent (b).

6. The method of claim 5, wherein, in the glycoside compound, the OH group in the substituent (b) is of R configuration.

a 7. The method of claim 5 or 6, wherein, in the glycoside compound, X is an integer of 21 to 25 and Y is an integer of 11 to 15.

a 8. The method of claim 6 or 7, wherein the glycoside compound is (2S,3S,4R)-1-( $\alpha$ -D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol.

a 9. The method of claim 1 ~~any one of claims 1 to 8~~, wherein the concentration of the glycoside compound or the salt

09721768.112700

thereof used in the culture is within the range from 0.1 ng/mL to 10 µg/mL.

10. The method of claim 9, wherein the concentration of the glycoside compound or the salt thereof is within the range from 0.01 µg/mL to 1 µg/mL.

*claim 1*  
11. The method of ~~any one of claims 1 to 10~~, wherein the culture is performed in the presence of GM-CSF and IL-4.

12. The method of claim 11, wherein the culture is performed in the presence of the monocyte conditioned medium (MCM).

*claim 1*  
13. The method of ~~any one of claims 1 to 12~~, wherein the culture is performed in the presence of a tumor antigen.

14. An activated human antigen-presenting cell prepared by activating human-derived antigen-presenting cells by the method of any one of ~~claims 1 to 13~~.

15. The activated human antigen-presenting cell of claim 14, wherein the human-derived antigen-presenting cell is selected from the group consisting of a CD1c positive cell, a human monocyte and a human dendritic

09721768.112700

a

cell.

16. The activated human antigen-presenting cell of claim 15, wherein the human-derived antigen-presenting cell is prepared from human peripheral blood.

17. The activated human antigen-presenting cell of claim 15, wherein the human-derived antigen-presenting cell is prepared from human umbilical cord blood.

18. The activated human antigen-presenting cell of claim 15, wherein the human-derived antigen-presenting cell is prepared from a human bone marrow cell.

19. The activated human antigen-presenting cell of claim 15, wherein the human-derived antigen-presenting cell is prepared from a human epidermis.

20. An agent for *in vitro* activation of human antigen-presenting cell which comprises, as an active ingredient, at least one of the glycoside compounds or salts thereof of claim 1.

21. The agent of claim 20, wherein at least one of <sup>said</sup> ~~the~~ glycoside compounds or salts thereof of claim 1 is used in combination with a tumor antigen.

09721768.112700

a

22. A method for treating cancer and infectious diseases including AIDS using the activated human antigen-presenting cell of any one of claims 14 to 19.

23. A use of the human activated human antigen-presenting cell of any one of claims 14 to 19 in the preparation of a medicine for treating cancer and infectious diseases including AIDS by application of an antigen-presenting cell therapy.

09721768.112700